Carl Lokko/iStock via Getty Images Alvotech ( ALVO ) is a commercial-stage company focusing on developing and manufacturing biosimilar versions of medications after those reference products lose exclusivity. ALVO also relies on regional partners to handle market access wherever appropriate. Interestingly, its biosimilars are gaining global traction but are seemingly facing some approval delays in the US due to manufacturing-site issues. The FDA issued a Form 483, which listed observations that I think ALVO should be able to address quickly. ALVO has also resubmitted its BLA for AVT05, a biosimilar to Johnson & Johnson’s ( JNJ ) Simponi, and AVT06, a biosimilar to Regeneron’s ( REGN ) Eylea. In my view, ALVO still has good prospects as long as its CMC setbacks resolve later this year, which is why I remain bullish on the stock. A Biosimilar Platform Worth Revisiting Alvotech is a commercial-stage biopharmaceutical company that develops biosimilar versions of major biologic drugs at a lower cost. The company was founded back in 2013, and it's currently headquartered in Reykjavik, Iceland. I previously covered ALVO last October, and since then, the stock has pulled back significantly. However, I believe their CMC bottleneck for biosimilars seems relatively fixable. As such, I felt it was worthwhile taking another look at this name. Source: Corporate Presentation. May 2026. As a quick recap, ALVO works with partners to bring its biosimilars to market. The company develops the drugs, but its partners handle sales in different regions. These partners include Teva ( TEVA ) in the US, STADA in parts of Europe, Fuji Pharma in Japan, and Advanz in Europe. ALVO also partners with Cipla in Australia and New Zealand, JAMP in Canada, and others in Latin America, the Middle East, and more. Commercial Momentum Meets FDA Friction With that in mind, since my last update, ALVO has made good commercial progress, and its approved products are selling well. ALVO’s revenues increased, par...

阿斯麦美股盘前涨超4%，现报1708.04美元。

The first JD Mall in Hong Kong. Photo: VCG JD.com Inc. will open its first physical JD Mall home appliance store in Hong Kong later this month, marking an important step in the e-commerce giant’s expansion into international markets. The Wan Chai outlet, which is set to begin operation on June 18, is part of its broader plan to establish six to eight experience-focused JD Mall stores in the city’s popular commercial districts like Sha Tin and Mong Kok over the next three years, the company said on Friday.

photo_Pawel/iStock via Getty Images Introduction For me, June is one of my favorite months of the year. Not only does it mark the official start to summer, but it's also a time when people are excited to get out and travel, relax, and enjoy the warmer weather. Personally, I enjoy taking small road trips and sitting by poolsides. With June getting off to a rocky start and stocks pulling back, I can honestly say I'm even more excited this year. At the time of writing, the Dow Jones Index ( DJI ) is down more than 400 points, creating what I believe are attractive buying opportunities in several high-quality stocks. Going forward, I think we will likely see stocks remain volatile as uncertainty surrounding inflation and rate hikes continues to build. However, long-term, income-focused investors should stay disciplined and continue dollar-cost averaging into quality businesses with strong fundamentals. In this article, I discuss which two dividend growth stocks I'm currently buying and why I believe both offer compelling upside potential over the next 24 to 36 months. Things Could Get Worse Markets are currently reacting to higher oil prices as the U.S. and Iran trade strikes. While talks of a deal between the two sides remain uncertain, one thing is likely: inflation will remain persistent for longer now. The spike in oil & fuel prices resulted in CPI hitting 3.8% , the third highest level since 2021. US Inflation Calculator As the conflict continues, rate hike chances continue to climb. Currently, economists predict a 41.3% chance of the FED hiking rates a quarter point by the end of the year. This is almost identical to the chances of rates staying where they are, much different compared to the beginning of the year, where we were expected to see multiple rate cuts in 2026. CME FedWatch The question is: What will happen if the FED does hike rates? I, personally, think we will see a market sell-off. Whether brief or prolonged, it could be the start of the bear market ...

(RTTNews) - Sempra Infrastructure, a subsidiary of utility company, Sempra (SRE), Monday announced that it has appointed Bhavesh Patel as its incoming chief executive officer as he will assume this role upon the closing of a KKR-led consortium's acquisition of a majority ownershi

If you owned Sprott Junior Copper Miners ETF (NASDAQ:COPJ) on Friday morning, you watched it open near $45.37 and close at $40.37, an 11% single-day tumble on June 5, 2026. A $10,000 stake at Thursday’s close became roughly $8,900 by Friday’s bell. For a fund that returned 93% over the prior twelve months, this was ... Broadcom Sneezed and COPJ Investors Lost 11% In A Day And Learned That Copper’s AI Story Has a Pause Button

顺丰同城公告，公司董事会已决定动用股份购回授权，视乎市场情况，不时于公开市场购回H股，动用资金上限为4亿港元。购回的H股将适时注销，资金来源为自有资金。建议股份购回实施期至下届年度股东会结束时、相关决议案通过后12个月届满之日或股东撤回授权之日（以最早者为准）。

中国驻伊朗大使馆8日发布安全提醒说，鉴于当前复杂严峻形势，中国驻伊朗使领馆再次提醒在伊中国公民加强安全防范和应急准备，及时向驻伊使领馆报备。同时，中国公民暂勿前往伊朗。提醒说，目前，伊首都德黑兰及西部地区空域处于关闭状态，在伊中国公民可重点关注伊马汉航空离伊航班恢复情况。同时，综合考虑口岸情况和当地及周边安全等因素，目前在伊中国公民可通过前往亚美尼亚、土耳其、土库曼斯坦的陆路通道离伊。（新华社）

Technip Energies wins Mozambique LNG contract for Eni, partners Reuters

Walter Cicchetti/iStock Editorial via Getty Images By Shannon L. Saccocia and Joe Amato The SpaceX ( SPCX ) IPO is without precedent in scale and structure. Its implications for markets, indices and portfolios extend well beyond the deal itself. A pipeline of mega-cap private companies is headed toward public markets, potentially reshaping the equity landscape when they arrive. SpaceX, Elon Musk's aerospace, satellite communications and artificial intelligence (AI) company, is the first. It has a target IPO valuation of around $1.8 trillion, raising capital of up to $75 billion in the process. To put that in context: oil major Saudi Aramco’s ( ARMCO ) 2019 offering, the largest in history, raised $25.6 billion on a $1.7 trillion valuation, while Alibaba’s ( BABA ) 2014 deal, long the benchmark for technology IPOs, raised $21.8 billion and was valued at $170 billion. The SpaceX IPO is 10 times larger than the latter, and we expect strong retail demand for the shares. But it will not be the only high-value public offering this year: Anthropic ( ANTHRO ) recently filed with the U.S. Securities and Exchange Commission, and we expect OpenAI ( OPENAI ) to be coming soon as well. Anthropic and OpenAI raised capital in private offerings earlier this year at valuations approaching $1 trillion. This wave of listings will dramatically reshape the indices most investors track and further test the depth of investor demand for mega-cap tech following the record $85 billion equity offering last week from Alphabet, Google’s parent. Three Businesses, One Valuation Following its February 2026 merger with xAI, SpaceX is effectively three businesses: a launch operation anchored by its Falcon 9 rocket—which commands approximately 90% of global commercial launch market share—Starlink, its satellite internet company targeting about 100 million subscribers and $140 billion in revenue by 2030 (according to the IPO underwriters), and xAI, its artificial intelligence subsidiary. By 2030, xAI ...

Honeywell International ( HON ) reaffirmed its full-year 2026 financial guidance on Monday and outlined preliminary expectations for the company that will remain after the planned June 29 spin-off of its aerospace division. Shares were little changed in premarket trading, erasing an earlier decline. The industrial conglomerate said it continues to expect 2026 sales of $38.8 billion to $39.8 billion, with organic revenue growth of 3% to 6%. Adjusted earnings per share are projected at $10.35 to $10.65, representing growth of 6% to 9% from the prior year. The company also maintained its forecast for free cash flow of $5.3 billion to $5.6 billion. Honeywell disclosed the updated outlook ahead of an investor conference call and its Investor Day scheduled for June 11. The aerospace separation is part of a broader restructuring effort that will leave the remaining company operating under the name Honeywell Technologies. Investors have been closely watching the transaction as industrial companies increasingly pursue breakups to simplify operations and unlock shareholder value. The guidance provides an early look at the earnings power and cash generation prospects of the post-spin business. For Honeywell Technologies, the company forecast 2026 sales of $19.9 billion to $20.2 billion and organic growth of 2% to 3%. Segment margins are expected to range from 19.8% to 20.3%, reflecting expansion of 220 to 270 basis points from 2025 levels. Adjusted earnings per share for the remaining company are projected at $3.95 to $4.15, representing growth of 22% to 28%, while free cash flow is expected to be about $2.0 billion. The outlook excludes results from the aerospace business and incorporates the planned sales of Productivity Solutions and Services and Warehouse and Workflow Solutions, both of which Honeywell expects to complete by the fourth quarter. The forecast also includes estimated contributions from the acquisition of Johnson Matthey's Catalyst Technologies business, which...

Duluth Holdings ( DLTH ) reported sales fell 4.1% year over year to $98.6M in Q1. Direct-to-consumer sales were down 8.7% to $57.1M due to declines in web traffic and web conversion due to reduced promotional activity partially offset by higher average order values. Meanwhile, retail store sales increased by 3.3% to $41.5M, driven by higher average order values in comparable stores, coupled with two new stores opened in the third quarter of 2025. CEO Stephanie Pugliese said customers are responding positively to core products, seasonal prints and patterns, and the newest marketing campaign. The retailer saw gross margin expand by 540 basis points to 57.4% of sales during the quarter. The increase in gross margin rate was primarily driven by an increase in average unit retail prices from reduced promotional activity, coupled with an improvement in product costs from the direct-to-factory sourcing initiative, partially offset by tariff costs. Non-GAAP EPS was reported at -$0.20 vs. -$0.39 consensus and -$0.44 a year ago. On the balance sheet, Duluth Holdings ( DLTH ) ended the quarter with $6.1M of cash and cash equivalents, $62.3M of net working capital, and $6.0M in outstanding debt on the $100.0M asset-based lending facility, resulting in approximately $100M of net liquidity. Looking ahead, Duluth Holdings ( DLTH ) sees FY26 sales landing in a range of $540M to $560M (midpoint $550M) vs. the consensus estimate of $555.6M. "O ur focus remains on delivering the core, high-quality, solution-based products that resonate most with our customers and creating an exceptional experience," stated Pugliese. Shares of Duluth Holdings ( DLTH ) were up 1.8% in premarket trading to $3.38 vs. the 52-week range of $1.82 to $4.66. More on Duluth Holdings Duluth Holdings Still Needs To Prove Itself Duluth Holdings: Showing Signs Of Stabilization Duluth Holdings Inc. (DLTH) Q4 2025 Earnings Call Transcript Duluth Holdings Non-GAAP EPS of -$0.20 beats by $0.19, revenue of $98.59M beats...

(RTTNews) - Brady Corp. (BRC), a developer and manufacturer of specialty products, on Monday announced that it appointed current board member Vineet Nargolwala as Chief Executive Officer, effective June 8.

Gold’s slump has followed Friday’s better-than-expected May U.S. employment report.

格隆汇6月8日｜WTI原油期货价格涨2.89%，报93.161美元/桶；布伦特原油期货价格涨2.62%，报95.525美元/桶。

格隆汇6月8日｜农业农村部畜牧兽医局官网显示，进入5月以来，鸡蛋价格已连续5周上涨。今年鸡蛋价格“逆势”上涨，不仅突破季节性规律，5月更呈现“周周攀升”特征。多名业内人士认为，这主要是受到前期产能收缩带来供应减量、阶段性需求集中释放等因素影响。2025年蛋价持续低位，养殖端缩减规模、淘汰蛋鸡，造成今年货源紧张，是本轮涨价的重要原因。业内人士认为，因产区库存延续低位，预计端午节前鸡蛋价格仍有冲高空间，但上涨动力逐步减弱，2026年下半年蛋价或将呈现“高位震荡、阶段性波动”特征。

Incyte ( INCY ) has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25B. Star Therapeutics will be eligible to receive up to $750M in additional payments upon the achievement of sales milestones, for a total potential consideration of up to $2B, subject to customary closing adjustments. The proposed acquisition would add VGA039, a novel monoclonal antibody, to Incyte’s hematology portfolio. VGA039 has the potential to be a universal hemostatic therapy that can treat numerous bleeding disorders, starting with all types of von Willebrand disease. The drug has advanced into a Phase 3 study designed to investigate the safety and efficacy of subcutaneous administration of VGA039 as prophylaxis for bleeding in patients with every type of von Willebrand disease. It has received fast track, orphan drug, rare pediatric disease, and breakthrough therapy designations from the U.S. Food and Drug Administration. “VGA039 fits directly into our strategy of building a top-tier growth company for the future,” said Bill Meury, CEO of Incyte. “It is a first-in-class, Phase 3 asset with compelling early data, a manageable development path and the potential to become an important new growth driver in one of our core therapeutic areas – hematology. The transaction has all of the attributes we look for in business development opportunities.” The transaction is an equity acquisition and is expected to close in the third quarter of 2026, pending Hart-Scott-Rodino review resulting in an expected R&D charge of approximately $1.25B that will be included in third quarter and full year 2026 GAAP and non-GAAP results. More on Incyte Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript Incyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript Incyte: Strong Business, But Risks Remain Incyte nears $2B deal for blood diso...

RDNA 5 won't arrive for at least another year, AMD GPU partners expect, as graphics card releases slow down PC Guide

美股纳斯达克100指数期货涨超1%，标普500指数期货涨0.59%，道琼斯指数期货涨0.15%。

Volato Group ( SOAR ) has signed a definitive agreement for a $2.2M strategic equity investment. The restricted common stock placement was led by medical technology firm Catheter Precision ( VTAK ) alongside other institutional technology investors. The capital injection significantly strengthens Volato’s balance sheet following the termination of its previously announced transaction with M2i Global. Management confirmed that the M2i termination will not disrupt its ability to pursue milestones under its accepted NYSE American compliance plan. The capital from this round will back Volato’s core strategic shift toward the artificial intelligence ecosystem, specifically targeting potential mergers and acquisitions (M&A) across AI software, data infrastructure, compute, and power generation sectors. Volato revealed it has already received two unsolicited, non-binding letters of intent regarding potential transactions involving AI data center infrastructure and dedicated power generation assets. The company already operates Parslee, an AI software platform specializing in document intelligence, and is actively developing Volato AI to deploy specialized AI agents into the aviation sector. Following the placement, Catheter Precision becomes Volato’s largest shareholder. The strategic investment remains subject to customary closing conditions, including the authorization of a supplemental listing application filed by Volato with the NYSE American exchange. More on Catheter Precision, Volato Group Volato Group receives NYSE American acceptance of compliance plan Volato Group uses full ATM capacity; convertible debt hits zero ahead of M2i merger Historical earnings data for Catheter Precision Financial information for Catheter Precision Financial information for Volato Group